The Ratio of the Absolute Lymphocyte Count to the Absolute Monocyte Count Is Associated with Prognosis in Hodgkin's Lymphoma: Correlation with Tumor-Associated Macrophages Full Text
The Oncologist, 06/22/2012
Exclusive author commentary
Koh YW et al. – This study suggests that the absolute lymphocyte count/absolute monocyte count (ALC/AMC) ratio may be a simple, inexpensive, and independent prognostic factor for overall survival (OS) outcome in patients with classical Hodgkin's lymphoma (cHL) and may have a role in the stratification of cHL patients in addition to the International Prognostic Score and tumor–associated macrophages (TAMs) content.
Jooryung Huh (06/22/2012) comments:
Hodgkin lymphoma is a seminal testimony to the effectiveness of modern multimodality treatment against cancer. However, there are still unresolved issues of overtreatment and undertreatment. Since most patients are cured and live many decades, it is imperative that they are spared of unnecessary treatments and their long-term sequelae. Our study suggests that ALC/AMC ratio at diagnosis may provide a powerful prognostic information, especially in limited stage disease. When used in combination with the International Prognostic Score and the recently advocated tumor macrophage content, ALC/AMC ratio may be a welcome addtion in the stratification of the risk of classical Hodgkin lymphoma patients for the choice of the optimal treatment.